Every 424B that Outlook Therapeutics, Inc. (OTLK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OTLK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLK filings page.
Outlook Therapeutics is a biopharmaceutical company commercializing LYTENAVA, the first FDA-, EU- and UK-approved ophthalmic bevacizumab for wet AMD. The company is offering 55,555,556 shares of common stock plus accompanying warrants to purchase 55,555,556 shares at a combined price of $0.99, for gross proceeds of about $55.0 million and estimated net proceeds of $51.1 million. Each warrant is immediately exercisable at $1.10 per share for five years. Underwriters have a 30‑day option for up to 8,333,333 additional shares and/or warrants.
Common shares outstanding are expected to rise to 242,672,554 (or 251,005,887 if the option is fully exercised), excluding warrant and option exercises and additional ATM issuances, implying meaningful dilution. Net proceeds, together with existing cash, are intended to fund the U.S. commercial launch of LYTENAVA and for working capital and general corporate purposes. Management estimates cash and cash equivalents of about $11.2 million as of June 30 2026 and discloses substantial doubt about the company’s ability to continue as a going concern without substantial additional capital. Outlook also carries a $19.8 million unsecured note to Atlas Sciences with quarterly redemption rights and a 7.5% exit fee, adding to financing risk.
Outlook Therapeutics is conducting a primary offering of common stock and five‑year warrants to purchase common stock, with each share sold together with a warrant. The warrants are immediately exercisable, separately tradable, and will not be listed.
The company has developed LYTENAVA, the first and only ophthalmic bevacizumab approved for wet age‑related macular degeneration in the US, EU and UK. Commercialization has begun in Germany and the UK, with expansion to Austria and other European countries, and a US launch is planned before December 31, 2026.
Outlook estimates cash and cash equivalents of about $11.2 million as of June 30, 2026 and discloses substantial doubt about its ability to continue as a going concern without significant additional capital. Recent financings include April and May 2026 direct offerings and sales under a $100 million at‑the‑market program, plus a $19.8 million unsecured note with Atlas Sciences. Net proceeds from this offering, together with existing cash, are intended mainly to fund the US commercial launch of LYTENAVA and for working capital and general corporate purposes.
Outlook Therapeutics, Inc. is registering for resale up to 17,258,065 shares of common stock on behalf of selling stockholders. These shares consist of 16,129,033 shares issuable upon exercise of Common Warrants and 1,129,032 shares issuable upon exercise of Placement Agent Warrants from an April 23, 2026 financing. The company is not selling shares in this offering and will not receive proceeds from selling stockholders’ resales, but will receive cash only if the warrants are exercised, at $0.31 per Common Warrant share and $0.3875 per Placement Agent Warrant share.
Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA, the first authorized ophthalmic bevacizumab for wet AMD in the EU and UK, with launches begun in Germany and the UK and additional EU launches planned. In the U.S., the FDA initially issued multiple Complete Response Letters but, after a Formal Dispute Resolution process, concluded substantial evidence of effectiveness has been established, and the company resubmitted its BLA in June 2026. The anti-VEGF retina market is described as approximately $3.6 billion in Europe, $8.5 billion in the U.S., and $16 billion globally. KPMG’s audit report includes a going-concern explanatory paragraph citing recurring losses, negative cash flows and an accumulated deficit.
Outlook Therapeutics is offering 8,539,709 shares of common stock at $0.5855 per share to a single accredited institutional investor.
In connection with this offering and effective upon closing, the company will amend outstanding warrants to purchase up to an aggregate of 15,488,570 shares so that the amended warrants have a reduced exercise price of $0.5855 per share. The offering is a direct sale without underwriters and delivery is expected on or about May 29, 2026.
The filing states the company had $7.7 million in cash and cash equivalents as of March 31, 2026, expects approximately $4.9 million net proceeds from this offering and estimates combined funds will fund operations into September 2026. The company also reports that the FDA granted an appeal after a Formal Dispute Resolution meeting and that it expects to resubmit the BLA for ONS-5010/LYTENAVA in June 2026.
Outlook Therapeutics proposes an at-the-market offering to sell up to $100,000,000 of common stock through H.C. Wainwright under a sales agreement dated May 13, 2026. The company may sell shares from time to time at prevailing market prices; proceeds are intended for working capital and general corporate purposes. The prospectus supplement states 120,863,252 shares outstanding as of May 7, 2026 and illustrates an illustrative pro forma outstanding share count of up to 524,577,422 shares under an assumed full $100.0 million raise. Sales are at Wainwright’s commercially reasonable efforts and Wainwright will receive a 3.0% commission; the offering is an ATM under Rule 415 and may be suspended or terminated under the Sales Agreement.
Outlook Therapeutics, Inc. is offering 16,129,033 shares of common stock at $0.31 per share in a registered offering, with gross proceeds of $5.0 million and estimated net proceeds to the company of approximately $4.2 million. The offering includes a concurrent private placement of detachable warrants to purchase up to 16,129,033 shares at a $0.31 exercise price; those warrants are unregistered and become exercisable only after stockholder approval and an amendment to increase authorized shares. Shares outstanding after this offering are expected to be 120,743,252, based on 104,614,219 shares outstanding as of March 31, 2026. The company reported $8.7 million in cash and cash equivalents as of December 31, 2025 and estimates that available funds, including recent financings, fund operations into August 2026. The company discloses multiple FDA Complete Response Letters for ONS-5010/LYTENAVA and substantial doubt about its ability to continue as a going concern.
Outlook Therapeutics, Inc. is offering 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares, at a combined public offering price of $0.25 per share and accompanying warrant. The offering includes placement agent warrants to purchase 1,400,000 shares (7.0% of shares sold) exercisable at $0.3125. Delivery of securities is expected on or about March 25, 2026.
The prospectus supplement states net proceeds to the company from a full subscription would be approximately $4.0 million after placement agent fees and estimated expenses, but this is a best-efforts offering with no minimum amount required to close. The company reported 84,614,219 shares outstanding as of March 20, 2026 and discloses substantial liquidity needs, existing convertible notes, recent FDA complete response letters for ONS-5010/LYTENAVA, and regulatory and financing risks described under "Risk Factors."
Outlook Therapeutics, Inc. is offering shares of common stock, pre-funded warrants and common warrants pursuant to a preliminary prospectus supplement to a registration statement (Reg. No. 333-278340). The offering pairs each share (or pre-funded warrant) with a common warrant exercisable for one share and expiring five years after issuance.
The company reports 84,614,219 shares of common stock outstanding as of March 20, 2026 and a last reported sale price of $0.35 per share on that date. As of December 31, 2025, cash and cash equivalents were $8.7 million. Debt highlights: a $33.1 million promissory note issued March 13, 2025 (the March 2025 Note) convertible into common stock, of which Avondale converted $6.9 million into shares at a weighted average price of $0.46 as of March 20, 2026; an agreement to issue an $18.36 million note on March 16, 2026 to partially repay the March 2025 Note, leaving approximately $9.7 million remaining under the March 2025 Note as of March 20, 2026.
The company discloses three FDA Complete Response Letters regarding its BLA for ONS-5010/LYTENAVA and ongoing regulatory engagement; the FDA has indicated confirmatory evidence of efficacy is required. Outlook has EU and UK marketing authorizations and launched in initial markets. The prospectus warns of substantial doubt about Outlook’s ability to continue as a going concern and Nasdaq noncompliance with the $1.00 bid-price rule, with a compliance date of August 17, 2026.